dalfopristin

Trade name: Synercid

Small moleculeapproved

Approved

Sep 21, 1999

Dalfopristin is a pristinamycin-like component of anti-bacterial drug called Synercid which also containes quinupristin (quinupristin:dalfopristin ratio is 30:70 (w/w)). The drug was approved by FDA and used for the treatment of skin diseases caused by Staphylococcus aureus or Streptococcus pyogenes. Dalfopristin binds to the RNA of the 50S ribosomal subunit and thus inhibits the late phase of protein synthesis. — NCATS

Clinical trial activity

1 trials · 3 clinical orgs · 2 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jun 1, 2000 (NCT00240747)

Timeline

1990s

Sep 21, 1999
Earliest FDA Approval
Sep 21, 1999
King Pharmaceuticals — NDA Secondary Org

2000s

Jan 1, 2000
Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Skin Diseases, Infectious (approved 1999)

Studied for

Gram-Positive Bacterial Infections · Phase 3

Mechanism of action

Bacterial 70S ribosomeINHIBITOR
Bacterial 70S ribosome inhibitor
23S RRNA

Combination products

synerci
with quinupristin
Also known as dalfopristin/quinupristin

Approval history

approvedPriority reviewAcceleratedSep 21, 1999

Chemistry & pharmacology

Loading structure…

SMILES

CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(C)=C\[C@@H](O)CC(=O)CC3=NC(=CO3)C2=O

Mol. weight: 690.847 g/mol
Lipinski Ro5: 2 violation(s)
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Delivery: Parenteral
Availability: Discontinued

Oral

Parenteral

Yes

Topical

Sources

Also known as

26-(2-diethylaminoethyl)sulfonylpristamycin iib
dalfopristin
dalfopristin
dalfopristin
dalfopristin
dalfopristin
dalfopristin
dalfopristin
dalfopristin
dalfopristin
dalfopristina
dalfopristina
dalfopristine
dalfopristine
dalfopristin mesilate
dalfopristin mesilate
dalfopristin mesilate
dalfopristin mesilate
dalfopristin mesilate
dalfopristin mesylate
dalfopristinum
dalfopristinum
rp 54476
rp-54476
rp-54476
rp-54476
rp-54476
synercid
synercid

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00240747	Phase 3	Jun 1, 2000	Aventis, Pfizer, Yale University

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (3)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Aventis	For profit	1	0	1	2000
Pfizer	For profit	1	1	1	2000
Yale University	Academic/Hospital	1	0	1	2000

3 organizations

Page 1 / 1

Marketing (2)

Organization	Org type	Relationship	Date
Aventis	For profit	NDA	—
King Pharmaceuticals	For profit	NDA2	Sep 21, 1999